| A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency |
Ongoing |
MRNA 3705 |
2 |
mRNA-3705-P101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) , King Abdullah Specialist Children's Hospital (Riyadh) |
| A Multicenter, Single Arm, Open Label Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Adult Patients with Iga Nephropathy Receiving Iptacopan on Top of Supportive Care |
Ongoing |
Iptacopan (LNP023) |
2a |
CLNP023A2201 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA) |
Ongoing |
Rilzabrutinib |
3 |
EFC17360 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A Retrospective Phase IV Study: Use of the clinical decision support tool (CDST) in predicting probability of response to vedolizumab in Middle Eastern Crohn’s Disease patients: the ME-VOICE study (Middle East Vedolizumab Outcomes probability In CDST Evaluation |
Ongoing |
Vedolizumab |
4 |
CCR-2024-2 |
King Khalid University Hospital (Riyadh) |
| DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY BTC01 - D781PC00001) |
Ongoing |
Trastuzumab-Deruxtecan,Rilvegostomig &Durvalumab |
3 |
D781PC00001 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease |
Ongoing |
Dupixent |
4 |
LPS18583 |
King Khalid University Hospital (Riyadh). |
| Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed PembrolizumabBiosimilar) versus Keytruda® in Combination with Chemotherapy for the Treatment of Patients with Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study) |
Ongoing |
MB12 (proposed pembrolizumab biosimilar) |
3 |
MB12-C-02-24 |
King Saud University Medical City (Riyadh) |
| Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus |
Ongoing |
Maralixibat |
3 |
MRX-802 |
King Faisal Specialist Hospital and Research Center (Riyadh). |
| A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma |
Ongoing |
Golcadomide / Rituximab |
3 |
CA0731003 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction |
Ongoing |
(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel |
3 |
ID-076A301 / SOS-AMI |
King Faisal Specialist Hospital and Research Center (Riyadh). |
